CELLeBRAIN is a South Korean clinical-stage biotechnology company developing stem cell-based gene and cell therapies for cancers and chronic degenerative diseases with limited treatment options. Its lead candidate CB-11 targets glioblastoma (GBM) and received US FDA orphan drug designation in February 2026; the program has completed a Phase 1 trial in recurrent GBM patients in Korea, with a Phase 1 in newly diagnosed patients underway. The company is preparing a US investigational new drug application targeted for 2027 and also develops regenerative therapies and genome-analysis technology.
1
Round
1
Industry
4
Tags
Sep 8, 2026
Latest raise
Funding activity · 1 round
Sep 8, 2026
$1M
Seed
Led by Lutz Birnbaumer
CELLeBRAIN Raises $1M Seed for Stem Cell Therapies Targeting Glioblastoma CELLeBRAIN (셀레브레인), a South Korean clinical stage biotechnology company, has raised $…
Read articlePricing
Public hubs orient you on the raise. Paid plans unlock live AI adoption signals across your market.
For individuals and small teams getting started with AI buyer intelligence.
$149
/month
Features
For outbound teams and agencies that need more coverage and faster signal cadence.
$249
/month
Features
Act on this raise
Funding is the starting point. VeilStrat shows whether capital is showing up as hiring, tools, and web activity you can sell into.
